Chapter from the book *Challenges in Rheumatology*
Downloaded from: http://www.intechopen.com/books/challenges-in-rheumatology

Interested in publishing with IntechOpen?
Contact us at book.department@intechopen.com
1. Introduction

Life expectancy increases in developed countries and results in a high prevalence of age-related diseases namely in women. Elderly subjects generate a huge demand on the social and health services linked to their disability and dependence. Besides the own effects of aging, the estrogenic deficiency, especially during menopause, is the major cause of degenerative diseases such as osteoporosis, skin aging, Alzheimer’s disease and osteoarthritis (OA) (Antonicelli et al., 2008; Candore et al., 2006; Elders, 2000; Felson & Nevitt, 1998; Pietschmann et al., 2008; Stovall & Pinkerton, 2008). OA is a worldwide public health problem which may affect different sites of the skeleton. In the Western world, at least 10% of the population has OA symptoms and 80% of the population will be potentially affected after the age of 70 years. Knee OA represents one of the major causes of morbidity and disability in relation to the worsening of quality of life (Elders, 2000). Pathogenesis of knee OA involves multiple factors including gender, weight, and genetics. Although age-dependent degenerative pathologies, especially OA, involve complex mechanisms in which the imbalance of the cytokines/growth factors plays a crucial role, it is more and more obvious that estrogens participate, with their receptors and modulators, to all of these diseases affecting connective tissues (Calleja-Agius & Brincat, 2009). Estrogens are steroidal hormones irreversibly synthesized from androgens via a crucial enzyme of steroidogenesis called aromatase, a member of cytochrome P450 superfamily, encoded by the CYP19 gene and being expressed in both sexes of many species (Simpson, 2003). Although non genomic action of estrogens is now recognized but these sexual hormones act often as signaling molecules that exert their effects by binding to estrogen receptors (ER) within the cells.

The estrogen-receptor complex interacts then with DNA to change the expression of estrogen-responsive genes. The two known estrogen receptors, ERα and ERβ, are present in numerous tissues other than those associated with reproduction, including bone, liver, heart, brain and cartilage and being selectively expressed in some targets; for instance ERβ is selectively expressed in lung and intestine. The presence of ERα and ERβ was detected in articular chondrocytes of different species, especially in human, rat, pig, cow and rabbit
(Classen et al., 2001; Dayani et al., 1988; Oshima et al., 2007; Ushiyama et al., 1999). The action of 17β-estradiol (17β-E2) on the cartilage appears to be intimately linked to the sex of individuals since it was shown that the binding capacity of 17β-E2 to its receptor was significantly higher in chondrocytes derived from male rather than female individuals (Nasatzky et al., 1994). In addition, 17β-E2 can stimulate the nuclear expression of its own receptors in chondrocytes and create therefore a loop that reinforces the activation effects of the hormone in this cell type (Richmond et al., 2000). Moreover, a strong correlation was found between the polymorphism of ESR1 gene encoding ERα and increased risk of OA in several populations (Bergink et al. 2003; Valdes et al., 2006). All these observations tend to prove that the cartilage is an estrogen-sensitive tissue, in which 17β-E2 would be likely to play a preponderant role in regulating chondrocyte homeostasis in joint diseases such as OA.

Even thought hormone replacement therapy (HRT) is the most efficient treatment against, at least, some of the degenerative pathologies mentioned above but studies confirm that risks linked to HRT can exceed the discounted benefits. As a consequence, it becomes important to address the question of the age-associated disorders and to find new targets to treat them. Selective Estrogen Receptor Modulators (SERM) like tamoxifen, raloxifen, fulvestrant and genistein have shown to be useful and attracted the attention of researchers (Cotter & Cashman, 2003; Khalil, 2010; Riggs & Hartmann 2003). A characteristic that distinguishes these substances from pure receptor agonists and antagonists is that their action is different in various tissues, thereby giving the possibility to selectively inhibit or stimulate estrogen-like action in various tissues. For instance tamoxifen (a first generation SERM) and raloxifen have been clinically used as antagonists of ER against breast cancer while they could be potentially agonists in bone and growth plate (Chagin et al, 2007; Nilsson et al, 2003). It has been proposed that these SERM could be used to replace natural estrogens to induce growth plate fusion reducing thereby the final height in girls expected to achieve extreme tall stature. Moreover, phytoestrogens (flavones, isoflavones, lignans) have aroused much interest as natural SERM and potential substitutes in the hormonal treatment of post-menopausal women, but they require much further investigation regarding their mechanism(s) of action and their safety (Dodin et al, 2003).

2. Estrogen synthesis and action

2.1 Estrogen synthesis via aromatase

Estrogens are steroidal hormones composed from 18 atoms of carbon and produced essentially in gonads, ovary and testis, but also in non reproductive tissues such as bone and adipose tissue. These lipophilic compounds irreversibly synthesized from androgens via a crucial enzyme of steroidogenesis called aromatase, a member of cytochrome P450 superfamily, encoded by the CYP19 gene and being expressed in both sexes of many species. In pre-menopausal women, estrogens such as 17β-E2 (the more estrogenic) and estrone are synthesized in ovary during follicular phase whereas estriol being produced essentially by placenta during pregnancy. After menopause, when ovary activity disappears, production of 17β-E2 from testosterone via aromatase is assumed by peripheral tissues like liver, adipose tissue, bone, vascular endothelium, chondrocyte and synovial cells (Simpson, 2003; Takeuchi et al., 2007; Tanko et al., 2008). Consequently, circulating 17β-E2 concentrations decrease drastically to 0.04-0.21 nM to reach those found in man (Chambliss & Shaul, 2002). Thus, estrogen action being localized and switch from endocrine to auto-,
intra- and/or paracrine actions. Due to their lipophilic feature, estrogen can diffuse into the cell through plasma membrane and induce estrogen-dependent intracellular signaling pathways and/or bind the intracellular receptors especially ER stimulating an estrogen-dependent response in target cells.

2.2 ER structure
In mammals, estrogens produced locally in different tissues, may exert various biological effects but are also responsible of the development of some pathological process such as hormone-dependent cancers. Estrogens exert their physiological and pathological effects through specific receptors considered as nuclear factors by binding target genes at a specific cis sequence called Estrogen Responsive Element (ERE).

The first study on estrogen receptor, published by Toft & Groski in 1966, demonstrated that a specific protein of rat uterus was able to bind specifically estrogens. Later, the gene of this protein has been cloned (Walter et al., 1985) and sequenced (Green et al., 1986) from mammal cancer epithelium (MCF-7) of a patient suffering from breast cancer. This protein is now recognized as ERα. A second gene (ERβ) has been also cloned from a cDNA library of the rat prostatic cells (Kuiper et al., 1996), being expressed selectively in some tissues and presenting more affinity for phytoestrogens.

It is now established that the majority of the normal and pathological action of estrogens is generally mediated through these two estrogen receptors ERα and ERβ which are members of nuclear receptor super family including progesterone, glucocorticoids, androgens and vitamin D receptors (Nuclear Receptor Nomenclature Committee, 1999; Germain et al., 2006; Mangelsdorf et al., 1995). In human, ERα is encoded by ESR1 gene located on chromosome 6 (6q25.1) whereas ERβ is encoded by ESR2 gene located on chromosome 14 (14q23.2). Both ESR1 and ESR2 genes encoding the estrogen receptor may undergo alternative splicing of mRNA. Most of these transcripts differ only in their 5'UTR (Untranslated Region) and will be mainly translated into a long form of ERα, recognized as ERα66 (Flouriot et al., 1998). However, a second form of ERα protein, derived from alternative splicing of exon 1A mRNA or a site of alternative translation initiation (AUG codon 174) was discovered and named ERα46 (Barrailler et al. 1999; Flouriot et al., 2000). After translation, the 46 kDa isoform is truncated of the 173 first amino acids of the long form of 66 kDa. ERα46 protein is thus composed of 422 amino acids, whereas ERα66 has 595 amino acids. Both ER isoforms are capable of inducing a physiological response after ligand binding. The 46 kDa isoform can heterodimerize with ERα66 and competitively inhibit the functions of ligand-independent trans activation of the long form of the receptor (Flouriot et al., 2000).

ERα and ERβ (530 amino acids) are structurally organized in six distinct functional domains (A to F) (Fig. 1). There are structural and functional similarities more or less strong between ERα and ERβ whose homology percentages vary significantly depending on the area considered. DNA binding domain (DBD) is conserved at about 97%, which means that both receptors can bind the same cis nucleotide sequences and thus activate transcription of identical target genes. However, there is only 55% homology at the level of ligand binding domain (LBD), indicating that ERα and ERβ have different ligand binding specificity. Finally, ERβ has only a truncated form of ligand-independent trans activation domain (AF-1), thus limiting its trans activation ability (Hall & McDonnell, 1999; Pearce & Jordan, 2004).
2.3 Genomic and non genomic action of estrogen

It is well established that estrogens act at target genes level to modulate their transcription via ER binding, so playing a transcriptional factor role recognized as ligand-dependent mechanism (Jensen & DeSombre, 1973). However, estrogen action becomes more complicated following the discovery of ERβ, or different ERα and ERβ isoforms but also with the identification of new plasma-associated membrane receptors. ERα and ERβ regulate thus estrogen-dependent genes expression through two distinct mechanisms: ERE-dependent genomic pathway and ERE-independent genomic pathway.

2.3.1 ERE-dependent genomic pathway

In this mechanism ERα and ERβ, following ligand fixation (estrogen, phytoestrogen, SERM), are subjected to homo- or hetero-dimerization, then ligand/ER complex move to the nucleus to bind directly ERE cis element (AGGTCAxxxTGACCT) (Hall et al., 2001) present in the promoter of target genes (Fig. 2). The determination of consensus sequences ERE and the fixation of ER will help to recruit transcriptional factors such as FOXA1 (Forkhead Box A1) or GATA4 (GATA binding protein 4), which will first ensure the chromatin remodeling necessary for ER binding. Ligand binding also allows the recruitment of transcription cofactors such as SRC-1 (Steroid Receptor Coactivator-1), GRIP-1 (Glucocorticoid Receptor Interacting Protein-1), CBP (CREB Binding Protein)/p300, or TRAP220 (Thyroid Hormone Receptor Activating Protein 220) (McKenna et al., 1999). The classic genomic pathway requires the activity of the two trans activation domains AF-1 and AF-2 that will allow the sequential and cyclic recruitment of different co-factors of transcription (Metivier et al., 2001).
2.3.2 ERE-independent genomic pathway
In this pathway, ERs will follow the classical mechanism described above except that they interact at the nuclear level with various transcriptional activator or repressor factors to regulate transcription of many estrogen-dependent genes that lack an ERE (Kushner et al., 2000; Paech et al., 1997; Sabbah et al., 1999; Safe, 2001).

Indeed, most estrogen-dependent genes have not necessarily in their regulatory regions a consensus ERE sequence. Therefore, estrogen will be involved in signaling pathways called ERE-independent which imply an interaction of ER with promoter of target gene through other transcription factors. In this case, the region of the receptor DBD does not bind to DNA, but participates in protein-protein interactions or recruitment of co-regulatory proteins to regulate expression of many genes. This mechanism of action is frequently used by nuclear receptors, which significantly complicates the decrypting of the effects induced by the ER (Gottlicher et al., 1998). Many of ER/protein interactions, which occur in cells to regulate transcription of many target genes, are composed for example of ER/AP-1 complex (c-Fos/c-Jun) (Ascenzi et al., 2006; Duan et al., 2008; Kushner et al. 2000; Matthews et al. 2006; Paech et al., 1997, Uht et al 1997; Webb et al., 1999), ER/Sp complex (Ascenzi et al., 2006; He et al., 2005; Kim et al., 2003; Saville et al., 2000; Stoner et al., 2004), and ER/NF-κB complex (Galien & Garcia, 1997; Stein & Yang, 1995). This latter is the only known mechanism of transcriptional repression induced by ER (Fig. 2).

For instance, after being activated by 17β-E2 binding, ER interact with the transcription factor NF-κB to control the transcriptional repression of certain genes such as IL-6 gene, which is involved in cartilage catabolism. Furthermore, in articular chondrocytes, it has been shown that 17β-E2 can counteract the effects of IL-1β by inhibiting nuclear translocation of the p65 subunit of NF-κB and therefore, binding of p65 to inducible nitric oxide synthase (iNOS) gene promoter (Richette et al., 2007). In addition, it has been suggested that ER and NF-κB compete for binding to the same transcriptional co-activators (p300/CBP and PCAF), and that in the case of activation of transcription by 17β-E2 through ER, the pool of these co-activators is mobilized predominantly by ER at the expense of NF-κB (Ansari & Gandy, 2007).

Therefore, estrogen/ER complex allows developing multiple physiological responses following hormonal stimulation by different signaling pathways and inter-connections with different trans factors and cis elements at the DNA level of target cells.

2.3.3 Non genomic signaling pathway
The non-genomic effects are defined as any action that does not involve transcriptional activity resulting from direct or indirect interaction of a nuclear receptor with the regulatory sequences of hormone-regulated genes. These effects are very rapid (in the order of several seconds to several minutes), incompatible with gene activation or protein synthesis. The effects of non-genomic estrogen receptors are often linked to signaling pathways that involve G protein-coupled receptors, ion channels or receptors linked to enzymes. 17β-E2 could modulate intracellular calcium or cAMP production and activate MAPK/ERK, PLC, PKA, or that of PI3K signaling pathways (Marino et al., 2002) (Fig 2). All these effects are not modified by inhibitors of transcription (actinomycin D) or translation (cycloheximide) (Losel & Wehling, 2003), confirming that they do not depend on a genomic action. In 1998, Beyer and Raab, by coupling 17β-E2 to BSA (Bovine Serum Albumin), thereby preventing it from crossing the plasma membrane, observed that 17β-E2 modulates intracellular calcium. Thus,
These different pathways occur in estrogen sensitive cells including ERE-dependent genomic, ERE-independent genomic (via Sp1, AP-1 and NF-κB) and membrane associated ER/G protein mechanisms. NF-κB pathway is the only inhibitory mechanism. In articular chondrocytes ERα66 homodimer complex binds predominantly Sp1 proteins to activate GC-box mediated trans activation of target genes such as Uridine diphospho-glucose deshydrogenase (UDPDG) and type II collagen (type II Col). Other mechanisms mediated by ERα46, ERβ, ERα and ERβ homo- and/or heterodimer and finally membrane associated ER/protein G need to be elucidated in articular chondrocytes. Note that 17β-E2 production from androgens like testosterone takes place via aromatase (CYP19) locally (intracrine effect) or in other cells (paracrine or endocrine effects). Adc, Adenylate cyclase; AP-1, Activating Protein-1; ERK, Extracellular signal Regulated Kinase; ERE, Estrogen Responsive Element; G, G protein; Hsp-90, Heat-shock protein 90; MAPK, Mitogen-Activated Protein Kinase; NF-κB, Nuclear Factor-κB; PI3K, Phosphatidyl Inositol 3-Kinase; PKA, Protein Kinase A; PLC, Phospholipase C; SERM, Selective Estrogen Receptor Modulator; Sp1, Specific Protein 1.

they confirm that this action is induced by a membrane ER. The existence of membrane estrogen receptor was discovered in the late 1970s in endometrial cells (Pietras & Szego, 1977). Various studies tempted to show that these membrane receptors are structurally similar to the classical cytoplasmic ER and that the α and β forms are represented (Chambliss & Shaul, 2002; Pappas et al., 1995; Razandi et al., 1999). More recently, a novel isoform of ERα was highlighted: ERα36. This 36 kDa protein lacks the trans activation domains AF-1 and AF-2 and has a DBD and a partial LBD, suggesting a membrane localization for this isoform (Wang et al., 2006). Also, estrogen binding sites localized at the membrane and the cytoplasm were detected in MCF-7 (Harrington et al., 2006). Since ER does not have a transmembrane domain,
it appears that palmitoylation of the classical form of the receptor is necessary for its membrane addressing (Acconcia et al., 2005; Ellmann et al., 2009). In addition, it has been demonstrated that ERα could be anchored to the plasma membrane through interactions with many membrane proteins such as caveolin 1 and 2, striatine or with adapter proteins like Shc and p130 Cas (Crk-associated substrate) (Cheskis et al., 2007).

### 2.3.4 Ligand-independent signaling pathway

In absence of 17β-E2, ER can be activated by phosphorylation via protein kinases A or C by extracellular signals like growth factors or cytokines, neurotransmitters, or by cell cycle regulators (Le Goff et al., 1994). Epidermal growth factor (EGF) mimics the effects of 17β-E2 in the mouse uterus. Similarly, insulin, insulin-like growth factor-I (IGF-I), dopamine or transforming growth factor-α (TGF-α) may activate ER. The main targets of these growth factors are the many serine residues present in the AF-1 domain of ER particularly Ser118 and Ser167 (Nilsson et al., 2001).

In summary, estrogens are involved in many signaling pathways, allowing fine control of cell and tissue functions.

### 3. Estrogen involvement in osteoarthritis

#### 3.1 Epidemiological observations and clinical data

OA is a worldwide public health problem which may affect different sites of the skeleton. In the Western world, at least 10% of the population present OA symptoms and 80% of the population will be potentially affected after the age of 70 years. Knee OA represents one of the major causes of morbidity and disability in relation to the worsening of quality of life. Pathogenesis of knee OA involves multiple factors including gender, weight, and genetics. Association between OA and estrogen deficiency during menopause has been firstly evoked by Cecil & Archer in 1925 following clinical observation. The hypothesis that estrogen deficiency may promote the development of OA has then been relied on the results of observational epidemiological studies. It is known that the frequency of knee OA is higher in women than in men; it is worsened after menopause and is lower in women receiving hormone replacement therapy (HRT) (Oliveria et al., 1995; Wilson et al., 1990). Although contradictions exist, some studies have shown that hysterectomy may also be associated with OA suggesting the potential role of estrogens to prevent these age-related diseases (Inoue et al., 1995; Spector et al., 1988; Spector et al., 1991). In addition, women with metastatic breast cancer when treated with aromatase inhibitors develop joint pains and cessation of aromatase inhibitors therapy resolved this joint pain (Burstein & Winer, 2007; Crew et al., 2007); aromatase inhibitors are widely used as adjuvant therapy in postmenopausal women with ER positive breast cancer (for review see Moslemi & Seralini, 2005). Moreover, an association of estrogen receptor (ERα and ERβ) polymorphisms has been found in patients with OA compared to unaffected subjects. All these data suggest a protective role of estrogen and HRT on OA through functional isoforms of ER. Such a protective effect of estrogen on the development of OA may suggest two potential mechanisms: a direct effect on cartilage and an indirect effect through modifications of sub-chondral bone remodelling. Nevertheless, some clinical studies based on symptomatic parameters failed to report any effect of HRT on cartilage metabolism, that’s why further studies are required to clearly demonstrate beneficial effects of estrogens on molecular regulations of articular cartilage homeostasis.
3.2 Biological *in vivo* and *in vitro* studies

*In vivo* animal studies indicate that estrogens may have a protective effect against OA, reversing or reducing the cartilage degradation in ovariectomized mice, rats, sheep and monkeys (Cuzzocrea et al., 2003; Ham et al., 2002; Høegh-Andersen et al., 2004; Oestergaard et al., 2006). However, the way by which estrogens act to prevent the pathogenesis of OA in these models remains unclear. It is supposed that estrogens prevent cartilage degradation by increasing production of growth factors such as insulin growth factor-I (IGF-I) and suppressing pro-inflammatory cytokines expression such as interleukin-6 (IL-6). A few data exist about the role of estrogen in regulating the synthesis of matrix compounds. *In vivo*, 17β-E2 prevents the degradation of collagen type II in the women treated with HRT (Mouritzen et al., 2003) but *in vitro*, it does not seem capable of modulating neosynthesis nor secretion of type II collagen in articular chondrocytes in primary culture (Ab-Rahim et al., 2008; Claassen et al., 2006). The measurement of serum C-terminal telopeptide of type II collagen (CTX-II) in bovine articular cartilage explants has determined that 17β-E2 significantly protected the cartilage degradation induced by tumor necrosis factor-α (TNF-α) and oncostatin M (Oestergaard et al., 2006). In similar *ex vivo* experiments, 17β-E2 can increase glycosaminoglycan (GAG) content of articular explants (Englert et al., 2006). Finally, the double invalidation of ERα and ERβ gene receptors (double knock-out ERα-/-, ERβ-/-) in mice aged of 6 months increases the number and size of osteophytes as well as a thinning of the sub-chondral plate, without changing the cartilage degradation (Sniekers et al., 2009). We demonstrated recently that 17β-E2 (the most potent among all estrogens) at physiologic doses, and ERα66 (wild type receptor) but not ERα46 (AF-1 deleted receptor) could up-regulate at both mRNA and protein levels UDP-glucose dehydrogenase (UDPGD) in primary cultured articular chondrocytes via specific protein 1 (Sp1) binding sites (Maneix et al., 2008). This enzyme is responsible of UDP-glucuronate synthesis which is the main component of GAG chains polymerization in cartilage: it plays an essential role in the elongation of GAG chains and their attachment to the axial protein of proteoglycans (PGs). Its decarboxylation provides UDP xylose, which serves to anchor chains of chondroitin sulfate (CS), dermatan sulfate (DS) and heparan sulphate (HS). Moreover, we also established that 17β-E2 increases the gene expression of type II collagen (COL2A1), the main collagen of hyaline cartilage, via trans activation domains AF-1 of ERα66 in coordination with the transcription factors Sp1, Sp3, p300 and Sox5 (Maneix et al, 2010). It would thus be a genomic mechanism ERE-independent. Finally, our preliminary results also showed that phytoestrogens such as apigenin and genistein could up-regulate the expression of UDPGD (unpublished data).

Overall, these data indicate that estrogen/phytoestrogens and their receptors can be considered as potent regulators of chondrocyte homeostasis and are pro-anabolic for extracellular matrix synthesis. This may have potential applications in the tissue engineering of articular cartilage and offer new perspectives to prevent and/or to treat OA.

4. Mechanisms of estrogen action in OA

4.1 Effects on growth factors and cytokines

17β-E2 can firstly interact with pathways affecting the synthesis and secretion of the key growth factors involved in the regulation of cartilage metabolism. So, TGF-β expression in the iliac crest chondrocytes is influenced by 17β-E2 in a biphasic manner: low concentrations of...
17β-E2 increase TGF-β expression whereas supra-physiologic doses decrease strongly its expression (Saggese et al., 1993). The concept of dose-dependence is confirmed by the majority of the studies on 17β-E2 in the articular cartilage where physiological doses of the hormone show to be protective when considering the structural integrity of tissue while supra-physiologic concentrations are often deleterious (Richette et al., 2003) (Fig. 3). Experiments on chondrocytes from ovariectomized monkeys treated with 17β-E2 showed that this hormone increases concomitantly the expression of the binding protein of IGF-I (IGFBP-2) and synthesis of PG (Richmond et al., 2000). In addition, the synovial fluid of these animals contains IGF-I twice more than untreated animals. Thereafter, it was shown that estrogen deficiency increases the sensitivity of cell response to certain pro-inflammatory cytokines through an increase in the number of receptors or cytokine cofactors amplifying consequently the effects of catabolic cytokines in these cells. Estrogen treatment in ovariectomized animals significantly reduced the production and secretion of pro-inflammatory cytokines in articular chondrocytes. This anti-inflammatory effect of 17β-E2 was highlighted by Le Bail et al. (2001) who showed that the localized production of 17β-E2 by synovial cells has inhibited the IL-6 secretion by articular chondrocytes. In addition, 17β-E2 can also reduce production of pro-inflammatory prostaglandins through a decrease in the mRNA steady-state levels of cyclooxygenase-2 (COX-2) in bovine articular chondrocytes (Morisset et al., 1998).

4.2 Metalloproteinases (MMPs) expression and activity
The majority of the beneficial effects of 17β-E2 in articular chondrocytes is focused on the inhibition of catabolic pathways. Thus, Lee et al. (2003) found that 17β-E2 decreases the secretion of the metalloproteinase MMP-1 in human osteoarthritic articular chondrocytes. In addition, 17β-E2 can antagonize the degradation of PGs and the expression and activity of MMP-1, MMP-3 and MMP-13 enzymes induced by IL-1β in rabbit articular chondrocytes (Richette et al., 2004). Especially, the effects of 17β-E2 on the expression of MMP-13 seem to be transmitted through the indirect binding of ERα66 at an AP-1 site in the promoter of MMP-13 gene (Lu et al., 2006). Like the mode of action of 17β-E2 on the expression levels of TGF-β, the effects of the hormone on the expression of MMPs and their inhibitors TIMPs (tissue inhibitors of MMPs) appear to be dose-dependent. Low doses of 17β-E2 decreased MMP-1/TIMP-1 and MMP-3/TIMP-1 ratios while higher concentrations have the opposite effect (Song et al., 2003).

4.3 Anti-oxidant effects
The generation of reactive oxygen species (ROS) contributes actively to the cartilage ECM degradation in OA, in particular by inducing a decrease in the synthesis of PGs. However, due to the structure of their phenol nuclei, 17β-E2 and its metabolites have anti-oxidant features (Liehr & Roy, 1998) that protect the cartilage degradation induced by ROS (Claassen et al., 2005). It is now established that 17β-E2 is a modulator of the redox status of chondrocytes. During the arthritic process, overproduction of nitric oxide (NO) is a consequence of the action of proinflammatory cytokines such as IL-1β or TNF-α that promote the activation of inducible nitric oxide synthase (iNOS) in OA chondrocytes. The iNOS gene is under the control of an estrogen-dependent promoter. Indeed, estrogen deficiency activates transcription of this promoter while a replacement therapy by 17β-E2 inhibits it in ovariectomized mice (Cuzzocrea et al., 2003). 17β-E2 can counteract the deleterious effects induced by IL-1β in rabbit articular chondrocytes by reducing the binding capacity of NF-κB.
Fig. 3. Role of 17β-E2 and estrogen receptor ERα /ERβ on joint cartilage homeostasis.

Col II, type II collagen; IGF-I, Insulin-like Growth Factor-I; IL, Interleukin; iNOS, Inducible Nitrogen Oxide Synthase; MMPs, Metalloproteinases; PGs, Proteoglycans; ROS, Reactive Oxygen Species; SERM, Selective Estrogen Receptor Modulators; TIMPs, Tissue Inhibitors MMPs; TGF-β, Transforming Growth Factor-β; TNF-α, Tumor Necrosis Factor-α; UDPGD, Uridine Diphospho-Glucose Dehydrogenase. The roles of SERM and phytoestrogens need to be clarified.

in the promoter of iNOS gene resulting in inhibition of nuclear translocation of this factor (Richette et al., 2007). This results in an inhibition of iNOS gene transcription and a subsequent reduction in NO production by chondrocytes.

4.4 Matrix components turn-over
To better understand the physiopathology of articular cartilage in osteoarthritis, Høegh-Andersen et al. (2004) have validated an experimental model of ovariectomized rats with modification in cartilage structure representative of in vivo pathological changes observed in early human osteoarthritis. In animals aged from 5 to 7 months, estrogen deficiency increases the erosion of the articular surface and accelerates the renewal of matrix molecules. This animal model also showed that the effectiveness of HRT in the prevention of cartilage loss is increased when estrogen is administered to the animal from its operation and not after a period of 3 weeks (Oestergaard et al. 2006). These works need to be compared with the many epidemiological data which showed that the benefits of HRT are strengthened when patients are treated at the first signs of menopause and continued their treatment over a period exceeding 5 years. The importance of prevention in the treatment of damaged cartilage appears essential.

4.5 Sub-chondral bone regulation
Within the joint, cartilage is not the only target tissue for estrogens. 17β-E2 also controls the renewal of the sub-chondral bone by maintaining a balance between the two players in bone
remodeling: osteoblasts that synthesize bone matrix and osteoclasts that are responsible for the resorption (bone loss) of existing bone. Estrogens inhibit osteoclasts activation and are therefore considered as inhibitors of bone resorption. The predominant mechanism that appears to be involved is the inhibition of IL-6 synthesis, the main cytokine involved in the activation of resorption. This inhibition of IL-6 synthesis by estrogens is mediated through the modification of NF-κB binding on IL-6 gene promoter; there is no direct binding of ER to DNA (Ray et al., 1994). Consequently, an increase of bone resorption, generally favoring the occurrence of osteoporosis, is frequently seen in women after menopause which is related to the decrease of circulating estrogen levels during this period (Reginster et al., 2003). In this context, HRT could effectively prevent postmenopausal osteoporosis.

Paradoxically, the frequency of OA and osteoporosis in postmenopausal women are most often inversely correlated, as reflected in the levels of osteocalcin, a marker of bone turnover, which are generally lower among women with OA than women without OA (for review: Dequeker et al., 2003). Patients suffering from OA of the knee are generally less subjected to bone loss. The increase in bone mass is a risk factor for incidence and development of knee and hip osteoarthritis. It was suggested that an increase in bone density in the area of the sub-chondral bone may induce bone stiffness and accelerate cartilage destruction. Thus, high bone density is associated with an increase of OA prevalence of the hip, hand and knee in postmenopausal women. However, high bone density increases risk of knee OA but protects against the progression of the disease once it is established. Therefore, bone loss in people with OA which is already established accelerates the progression of the disease. Indeed, Jacobsen et al. (2007) showed that the reduction of intra-articular space in the hip was correlated with the decrease in mineral density of sub-chondral bone in postmenopausal women. It was suggested that the alteration of bone structure can cause changes in the load distribution within the joint and promote the development of OA (Sniekers et al. 2008). In this case, the favorable effect of estrogen on cartilage may be due in part to the anti-resorption effect of 17β-E2 on bone.

5. Phytoestrogen and Selective Estrogen Receptor Modulators (SERM)

During the second half of the 20th century, HRT has been repeatedly promoted as the only pharmacological approach allowing a global prevention of all disorders related to or potentiated by estrogen deprivation. Recently, the risk/benefit profile of HRT has been severely challenged because of apparent increased risks of invasive breast cancer, coronary heart disease events, stroke and pulmonary embolism among treated women. These new findings imply a careful reassessment of the current evidence justifying the prescription of HRT for the prevention of the management of chronic disorders. The many contradictions recorded concerning benefit/risk effects of HRT are often related to differences in methodology and criteria used in measuring the effects of estrogen therapy in clinical studies. Indeed, analysis based strictly on symptomatic parameters showed that HRT had no effect or even adverse effects on the progression of OA (Von Muhlen et al., 2002). Conversely, more advanced techniques of magnetic resonance imaging showed that recipients of long term HRT (5 years or more) had a volume of articular cartilage largest in the knee than women having never taken any treatments (Wluka et al., 2001). As to the evolution of medical imaging techniques and advances in the diagnosis of OA, it appears that estrogens have a strong potential for preventing disease and preserving the structural integrity of the articulation among postmenopausal women. Thus, recent clinical trials of
consortium “Women’s Health Initiative” showed that women treated with equine estrogens over a period of 7 years had 17% lower risk to undergo a hip replacement compared to control group (Cirillo et al., 2006). Finally, an in vivo study performed on 180 ovariectomized monkeys for 3 years found that HRT reduced the severity of arthritic lesions, through attenuation of the PGs loss and reducing the number of osteophytes in these animals (Ham et al., 2002). Given its chondroprotective potential, it would seem that HRT is capable of modulating chondrocyte metabolism. Studies have also shown that SERM and phytoestrogens may have beneficial effect on cartilage metabolism and to alleviate OA symptoms (Arjmandi et al, 2004; Bassleer et al., 1996; Guiducci et al., 2005; Tsai et al., 1992).

It has been shown that when administered at a clinically relevant dose in young male rats, tamoxifen causes persistent retardation of longitudinal and cortical radial bone growth through systemic suppression of IGF-I production and local effects on the growth plate cartilage; it increases in chondrocytes proliferation/apoptosis and decreases the number of hypertrophic chondrocytes (Karimian et al., 2008). Similarly, raloxifen could act as estrogen agonist on the growth plate of ovariectomized immature rabbits, accelerating growth plate senescence and thus hastening epiphyseal fusion (Nilsson et al, 2003).

Besides estrogens, natural molecules such as phytoestrogens (estrogen-like compounds in plants) sharing structural and functional homologies with endogenous estrogens, could also act (even thought at micromolar concentrations) as agonists and/or antagonists in hormonestensitive target cells. Scientists are now interested in the tissue-selective activities of phytoestrogens considering anti-estrogenic effects in reproductive tissue that could help to reduce the risk of hormone-associated cancers (breast, uterine, ovarian, and prostate), while estrogenic effects on bone and cardiovascular system for instance could favor the maintenance of bone density and protect against atherosclerosis respectively. Moreover, it has been suggested that the consumption of dietary phytoestrogens (soja isoflavones, lignans, etc.) may have beneficial effects on bone health at all stages of life. That’s why phytoestrogens have aroused much interest as potential substitutes in HRT of postmenopausal women, but they require much further investigation regarding their mechanism of action and their safety. Like estrogens, phytoestrogens may act via genomic and non genomic pathways. The most relevant molecular actions of phytoestrogens are those mediated by ERs. They may act on protein tyrosine kinase, MAP kinase, topoisomerase II and at all stages of cell cycle and apoptosis. They can also change the response to growth factors and cytokines. Genistein up to 100 μM reduces the production of lipopolysaccharide (LPS)-stimulated pro-inflammatory molecules (COX-2, NO) but not that of COX-1 responsible of releasing prostaglandins in normal human chondrocytes (Hooshmand et al., 2007). When tested on human chondrocytes and chondrocytic cell line CHON-002, bavachin, a flavonid phytoestrogen isolated from Psoralea corylifolia, potentially protected cartilage from inflammation-mediated damage in joints of OA through decreasing IL-1beta-induced activation of IKK-IκB alpha-NF-κB signaling pathway (Cheng et al., 2010). Formononetin, a phytoestrogen isolated from Astragalus membranaceus showed to have biphasic positive effects on human normal osteoblasts and OA sub-chondral osteoblasts by modifying their biological synthetic capacities (Huh et al., 2010). Using female bovine articular chondrocytes, it has been demonstrated that the stimulating effect of insulin on GAGs sulfate incorporation was enhanced significantly after preincubation of cells with 10^{-11} -10^{-5} M daidzein or 10^{-9} -10^{-5} M genistein but not by 17β-E2 (Claassen et al., 2008). More recently, xanthohumol, a prenylflavonoid extracted from hop, showed to prevent hyaluronan overproduction as well as PG and collagen loss in bovine chondrocytes;
hyluronan overproduction is considered as an early reaction in OA followed by PG loss and collagen degradation (Stracke et al., 2001). However, additional research is critical to determine how phytoestrogens act on cartilage cells to obtain a more complete understanding of the effects.

6. Conclusion

From epidemiological, clinical, in vivo and in vitro studies, a huge amount of data consistent with the fact that estrogens and their receptors can now be considered among the main players involved in the chondrocyte homeostasis and participate in cartilage protection from degradation and erosion occurring during menopause. Indeed, once ligand/ER complex is formed, estrogens such as 17β-E2 could act with ER to induce or to inhibit trans activation of target genes of chondrocytes, the predominant cells of articular cartilage allowing expression of the specific chondrogenic markers such as UDPGD, PGs, type II collagen or inhibition of catabolic markers such as metalloproteinases and interleukins. There are different pathways by which estrogen and ER may interact with target genes in chondrocytes but it seems that Sp1 mediated trans activation being preferentially used in this cell type. In this mechanism ER needs AF-1 sequence (ligand-independent trans activation domain) to exert its action on GC boxes via Sp1 in target genes. In addition, some molecules sharing structural and functional features with estrogens like SERM and phytoestrogens can mimic estrogenic action and are therefore useful to repair cartilage erosion or might contribute at least to protect premenopausal joint cartilage and to maintain its homeostasis in a prevention strategy but these molecules need further investigation and deserves more attention from the scientific community to prove their safety and efficacy.

7. Key points

Osteoarthritis, cartilage, chondrocytes, estrogens, phytoestrogens, selective estrogen receptor modulators, hormone replacement therapy, menopause.

8. References


Rheumatology is a subspecialty of medicine that focuses on the biology, cause, diagnosis and the treatment of a variety of musculoskeletal and other systemic diseases. The field of rheumatology is expanding rapidly and several very exciting developments have occurred during the recent years. Firstly, there has been a new dramatic understanding of the nature of inflammation and the possibility of specifically regulating the aberrant immune inflammatory response. Secondly, an understanding of pathogenesis has lead to the development of new, more targeted therapies. Challenges in Rheumatology has assembled an impressive group of international experts who have studied specific aspects of certain rheumatic diseases and have extensive experience either in pathophysiology, or with the in-depth diagnosis and/or management of rheumatic patients. They communicate their knowledge and experience to the reader in chapters that are conveniently organized as pathophysiology, clinical manifestations and diagnosis of selected rheumatic diseases, medical and perioperative orthopedic management, and the economic impact of rheumatic diseases. We hope that this book will help trainees become better physicians and scientists, and that it will help practicing rheumatologists to provide better care, and ultimately, improve the quality of life of our patients.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: